Value
1.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 3.0 |
- ▸Expensive valuation
ALMR · Why this verdict
Why Alamar Biosciences (ALMR) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Alamar Biosciences is growing revenue 99% YoY as an industry leader, but the stock has already reached its prior analyst target with a failed asymmetry gate, a momentum score sitting exactly at the pass-fail line, and an expensive, leverage-penalized valuation, leaving little room for further re-rating.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing 99% YoY, and the peer-ranking model flags the company as an industry growth leader. Growth breakdown | Revenue growth should stay well above the sector average for the growth-leader thesis to hold over the next 12 months. | →Stable |
| CounterTriple-digit growth off a small base is common in early-stage medical device companies and often decelerates sharply as the base grows. | ||
The stock has already reached its prior analyst price target, leaving only about 0.6% modeled upside from current levels. Warnings | Modeled upside should expand meaningfully if analysts issue higher targets following continued growth. | Tripped↑Improving |
| CounterA 99% revenue growth rate could justify analysts raising targets soon, which would quickly restore modeled upside. | ||
The asymmetry ratio sits at just 0.04, failing the 1.5 minimum bar, while momentum sits exactly at its own 4.5 pass-fail threshold, a fragile setup on both fronts. Engine gate (failed) | Asymmetry should climb meaningfully above 1.5 and momentum should clear 4.5 with room to spare for the setup to strengthen. | ↑Improving |
| CounterA momentum score sitting exactly at the threshold could just as easily resolve upward given the underlying growth strength. | ||
The stock carries an expensive valuation alongside a leverage penalty applied by the scoring engine given a D/E of 1.9. Bear case | Debt-to-equity should decline from the current 1.9 for the leverage penalty to ease. | ↑Improving |
| CounterA growth-stage medical device company may use leverage strategically to fund expansion without it signaling financial distress. | ||
Revenue is growing 99% YoY, and the peer-ranking model flags the company as an industry growth leader.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay well above the sector average for the growth-leader thesis to hold over the next 12 months.
CounterTriple-digit growth off a small base is common in early-stage medical device companies and often decelerates sharply as the base grows.
The stock has already reached its prior analyst price target, leaving only about 0.6% modeled upside from current levels.
Tripped↑ImprovingWarnings
- Expectation
- Modeled upside should expand meaningfully if analysts issue higher targets following continued growth.
CounterA 99% revenue growth rate could justify analysts raising targets soon, which would quickly restore modeled upside.
The asymmetry ratio sits at just 0.04, failing the 1.5 minimum bar, while momentum sits exactly at its own 4.5 pass-fail threshold, a fragile setup on both fronts.
↑ImprovingEngine gate (failed)
- Expectation
- Asymmetry should climb meaningfully above 1.5 and momentum should clear 4.5 with room to spare for the setup to strengthen.
CounterA momentum score sitting exactly at the threshold could just as easily resolve upward given the underlying growth strength.
The stock carries an expensive valuation alongside a leverage penalty applied by the scoring engine given a D/E of 1.9.
↑ImprovingBear case
- Expectation
- Debt-to-equity should decline from the current 1.9 for the leverage penalty to ease.
CounterA growth-stage medical device company may use leverage strategically to fund expansion without it signaling financial distress.
Per-dimension breakdown
Quality
5.1/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 7.7 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 8.0 |
| Piotroski F | 10.0 |
- ▸Wide economic moat
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 82% YoY
Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 5.0 |
- ▸Volume accumulation (rising OBV)
Sentiment
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.9 |
| Analyst rating | 5.0 |
| Price target | 5.2 |
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.0 |
| quality rank | 0.8 |
| growth rank | 9.7 |
- ▸Industry growth leader
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.8 |
| support resistance | 3.7 |
| 52w position | 7.1 |
Risk (lower is worse)
4.3/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 7.2 |
| days to cover | 0.7 |
| volatility | 0.0 |
| debt equity | 9.3 |
Catalyst
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=+1|ENTRY_STICKY:WITHIN_BANDPassed (7)
- MOMENTUM:7.1>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:83d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.8=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.78
Upside
-11.7%
Downside
15.0%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.3B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:7.1>=5.5. Top dim: Growth at 10.0; weakest: Value at 1.8. No conviction either direction.
The strongest dimensions are Growth at 10.0, Catalyst at 7.6, and Insider at 7.3; the weakest are Value at 1.8, Technical at 3.9, and Risk (lower is worse) at 4.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.78 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Revenue Growth Industry Leader
Trip ifRevenue growth falls below 40% YoY from the current 99%.
- P2Target Already ReachedTripped
Trip ifModeled upside to price target rises above 15% from the current 0.6%.
- P3Failed Asymmetry At Momentum Floor
Trip ifAsymmetry ratio rises above 1.5 from the current 0.04.
- P4Expensive Valuation Leverage Penalty
Trip ifDebt-to-equity ratio falls below 1.0 from the current 1.9.